Cargando…
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
BACKGROUND: Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS...
Autores principales: | Shitara, Kohei, Doi, Toshihiko, Hosaka, Hisashi, Thuss-Patience, Peter, Santoro, Armando, Longo, Federico, Ozyilkan, Ozgur, Cicin, Irfan, Park, David, Zaanan, Aziz, Pericay, Carles, Özgüroğlu, Mustafa, Alsina, Maria, Makris, Lukas, Benhadji, Karim A., Ilson, David H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013328/ https://www.ncbi.nlm.nih.gov/pubmed/34997449 http://dx.doi.org/10.1007/s10120-021-01271-9 |
Ejemplares similares
-
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
por: Mansoor, Wasat, et al.
Publicado: (2021) -
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
por: Van Cutsem, E., et al.
Publicado: (2022) -
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial
por: Ilson, David H., et al.
Publicado: (2019) -
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study
por: Tabernero, J., et al.
Publicado: (2021) -
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)
por: Shitara, Kohei, et al.
Publicado: (2023)